Long non-coding RNAs in schizophrenia : Genetic variations, treatment markers and potential targeted signaling pathways
Copyright © 2023. Published by Elsevier B.V..
Schizophrenia (SZ), a complex and debilitating spectrum of psychiatric disorders, is now mainly attributed to multifactorial etiology that includes genetic and environmental factors. Long non-coding RNAs (lncRNAs) are gaining popularity as a way to better understand the comprehensive mechanisms beneath the clinical manifestation of SZ. Only in recent years has it been elucidated that mammalian genomes encode thousands of lncRNAs. Strikingly, roughly 30-40% of these lncRNAs are extensively expressed in different regions across the brain, which may be closely associated with SZ. The therapeutic and adverse effects of atypical antipsychotic drugs (AAPDs) are partially reflected by their role in the regulation of lncRNAs. This begs the question directly, do any lncRNAs exist as biomarkers for AAPDs treatment? Furthermore, we comprehend a range of mechanistic investigations that have revealed the regulatory roles for lncRNAs both involved in the brain and the periphery of SZ. More crucially, we also combine insights from a variety of signaling pathways to argue that lncRNAs probably play critical roles in SZ via their interactive downstream factors. This review provides a thorough understanding regarding dysregulation of lncRNAs, corresponding genetic alternations, as well as their potential regulatory roles in the pathology of SZ, which might help reveal useful therapeutic targets in SZ.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:260 |
|---|---|
| Enthalten in: |
Schizophrenia research - 260(2023) vom: 16. Okt., Seite 12-22 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cao, Ting [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 25.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.schres.2023.07.027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360426964 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360426964 | ||
| 003 | DE-627 | ||
| 005 | 20231226083005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.schres.2023.07.027 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360426964 | ||
| 035 | |a (NLM)37543007 | ||
| 035 | |a (PII)S0920-9964(23)00249-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cao, Ting |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long non-coding RNAs in schizophrenia |b Genetic variations, treatment markers and potential targeted signaling pathways |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 25.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a Schizophrenia (SZ), a complex and debilitating spectrum of psychiatric disorders, is now mainly attributed to multifactorial etiology that includes genetic and environmental factors. Long non-coding RNAs (lncRNAs) are gaining popularity as a way to better understand the comprehensive mechanisms beneath the clinical manifestation of SZ. Only in recent years has it been elucidated that mammalian genomes encode thousands of lncRNAs. Strikingly, roughly 30-40% of these lncRNAs are extensively expressed in different regions across the brain, which may be closely associated with SZ. The therapeutic and adverse effects of atypical antipsychotic drugs (AAPDs) are partially reflected by their role in the regulation of lncRNAs. This begs the question directly, do any lncRNAs exist as biomarkers for AAPDs treatment? Furthermore, we comprehend a range of mechanistic investigations that have revealed the regulatory roles for lncRNAs both involved in the brain and the periphery of SZ. More crucially, we also combine insights from a variety of signaling pathways to argue that lncRNAs probably play critical roles in SZ via their interactive downstream factors. This review provides a thorough understanding regarding dysregulation of lncRNAs, corresponding genetic alternations, as well as their potential regulatory roles in the pathology of SZ, which might help reveal useful therapeutic targets in SZ | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Dysregulation | |
| 650 | 4 | |a Interactive factors | |
| 650 | 4 | |a LncRNA | |
| 650 | 4 | |a SZ | |
| 650 | 4 | |a Treatment response | |
| 650 | 7 | |a RNA, Long Noncoding |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Zhang, ShuangYang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, CuiRong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, LiWei |e verfasserin |4 aut | |
| 700 | 1 | |a Jiao, ShiMeng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, BiKui |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, HuaLin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Schizophrenia research |d 1989 |g 260(2023) vom: 16. Okt., Seite 12-22 |w (DE-627)NLM013111655 |x 1573-2509 |7 nnns |
| 773 | 1 | 8 | |g volume:260 |g year:2023 |g day:16 |g month:10 |g pages:12-22 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.schres.2023.07.027 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 260 |j 2023 |b 16 |c 10 |h 12-22 | ||